Loading...
•
Dec 31, 2023
Korro Bio Q4 2023 Earnings Report
Reported full year 2023 financial results and highlighted recent progress.
Key Takeaways
Korro Bio reported a strong cash position of $166.1 million and reiterated progress on KRRO-110 and other pipeline candidates.
On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024.
Demonstrated the versatility of Korro’s RNA editing platform by generating de-novo protein variants via multiple targets in non-human primates (NHPs).
Demonstrated greater than 50% editing using GalNAc conjugates in the liver with subcutaneous administration in a preclinical mouse model.
Ended 2023 with $166 million of cash and cash equivalents, including $117 million of proceeds from a successful private financing completed in November 2023, providing cash runway into 2026.
Korro Bio
Korro Bio
Forward Guidance
Korro Bio anticipates several milestones in 2024, including a regulatory submission for KRRO-110 in the second half of 2024 and further progression of pipeline programs.
Positive Outlook
- Regulatory filing for KRRO-110 in AATD on track for the second half of 2024.
- Anticipated interim clinical readout for KRRO-110 in AATD in the second half of 2025.
- Advancement of KRRO-110 through a potential interim clinical readout.
- Progression of additional product candidates through the Company’s pipeline.
- Demonstration of OPERA applicability across additional tissue types.
Challenges Ahead
- Risks inherent in biopharmaceutical development.
- Risks associated with pre-clinical studies and clinical trials.
- Risks associated with obtaining regulatory approvals and protecting intellectual property.
- Risks associated with general economic conditions.
- The inability to recognize the anticipated benefits of the recently completed merger.